Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Apogenix Obtains Roughly $3.66M to Further Cancer and Inflammatory Disease Initiatives

Focus is on developing IL-4 and CD95 ligand inhibitors, and lead candidate is expected to enter a Phase II glioblastoma trial in 2010.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »